Rheumatoid arthritis is an autoimmune inflammatory disease in which the immune system attacks joint lining tissues, causing chronic pain, swelling, and stiffness. It most commonly affects small and medium joints and can also involve extra-articular organs such as the lungs, heart, and eyes.
The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
The IRA's price controls could raise long-term drug prices by 21% for the first 25 selected drugs, while Medicare's $2,000 out-of-pocket cap encourages plans to favor IV over equally effective subcutaneous versions.
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
Researchers developed a cell-free cartilage scaffold that guides bone regeneration without strong immune reactions. The off-the-shelf graft, tested in animals, could replace costly patient-specific grafts. Human trials are being prepared.
XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company specializing in True Human monoclonal antibodies. Pipeline candidates include Natrunix and Hutrukin. The company is held by small-cap value ETFs.
Colorado's Prescription Drug Affordability Board imposed a price cap on Enbrel, making it the first U.S. state to cap a specific drug's price. Amgen is suing to block the cap, arguing it interferes with federal patent law protections for innovative drugs. The federal court is considering whether to issue a temporary injunction, with a ruling expected soon.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
Kyverna Therapeutics reports positive long-term follow-up results for its CAR-T therapy miv-cel in generalized myasthenia gravis, with plans to submit a biologics license application in the first half of 2026. The company has $279.3 million in cash providing runway into 2028 to fund launch and Phase 3 trials.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion to USD 5.73 billion by 2035 at a 19% CAGR. Monoclonal antibodies hold almost 55% of market share, while oncological disorders dominate demand.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779616 |
Study of PTC844 in Participants With Active Rheumatoid Arthritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07772687 |
Prospective Analysis of Blood Flow Restriction Training in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Compared to Conventional Strength Training |
COMPLETED | NA |
| NCT07754552 |
Development and Evaluation of the Effectiveness of the SMART-HAND Protocol for Hand Rehabilitation in Patients With Rheumatoid Arthritis |
NOT_YET_RECRUITING | NA |
| NCT07737470 |
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research |
NOT_YET_RECRUITING | |
| NCT07715045 |
Umbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled Trial |
COMPLETED | PHASE2 |
| NCT07712939 |
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases |
RECRUITING | PHASE1 |
| NCT07704580 |
Phase 1b/2 Study of IV Sarilumab in Adult With RA |
RECRUITING | PHASE1/PHASE2 |
| NCT07680101 |
Intra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration. |
NOT_YET_RECRUITING | NA |
| NCT07678034 |
Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System |
RECRUITING | |
| NCT07649265 |
A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body |
NOT_YET_RECRUITING | PHASE1 |
